Atosiban

Research use only, not for human use.

A nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist.

A nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist; inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane; is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Other Indication Approved.

Atosiban inhibits the oxytocin-mediated release of IP3 from the myometrial cell membrane. There is reduced release of intracellular, stored calcium from the sacroplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, Atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.

The posterior pituitary hormones, oxytocin and arginine vasopressin, differ in structure by only two amino acids, and Atosiban influences physiological effects of arginine vasopressin on the feto-maternal cardiovascular and renal systems. In late-gestation sheep, the administration of Atosiban for 1 hour fails to induce fetomaternal cardiovascular changes.Atosiban blocks the activation of oxytocin-receptor-expressing neurons in the parabrachial nucleus of mice.

RW-22164 | RWJ-22164

GPCR/G Protein

OXTR

Others

Other Indications

Other Disease

90779-69-4

994.1886

C43H67N11O12S2

>98% (HPLC)

DMSO: < 10.3 mg/mL

CCOc1ccc(C[C@H]2NC(CCSSC[C@@H](C(N3CCC[C@H]3C(N[C@H](C(NCC(N)=O)=O)CCCN)=O)=O)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@H]([C@H](CC)C)NC2=O)=O)=O)CC(N)=O)=O)=O)cc1

Glycinamide, O-ethyl-N-(3-mercapto-1-oxopropyl)-D-tyrosyl-L-isoleucyl-L-threonyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-ornithyl-, cyclic (1→5)-disulfide

(-20℃)

With Ice Pack

≥ 2 years